Inhibiting HER3-Mediated Tumor Cell Growth with Affibody Molecules Engineered to Low Picomolar Affinity by Position-Directed Error-Prone PCR-Like Diversification

• Magdalena Malm,

  Affiliation Division of Protein Technology, School of Biotechnology, KTH Royal Institute of Technology, Stockholm, Sweden

  ⨯
• Nina Kronqvist,

  Affiliation Division of Protein Technology, School of Biotechnology, KTH Royal Institute of Technology, Stockholm, Sweden

  ⨯
• Hanna Lindberg,

  Affiliation Division of Protein Technology, School of Biotechnology, KTH Royal Institute of Technology, Stockholm, Sweden

  ⨯
• Lindvi Gudmundsdotter,

  Affiliation Affibody AB, Stockholm, Sweden

  ⨯
• Tarek Bass,

  Affiliation Division of Protein Technology, School of Biotechnology, KTH Royal Institute of Technology, Stockholm, Sweden

  ⨯
• Fredrik Y. Frejd,

  Affiliations Affibody AB, Stockholm, Sweden, Unit of Biomedical Radiations Sciences, Uppsala University, Uppsala, Sweden

  ⨯
• Ingmarie Höidén-Guthenberg,

  Affiliation Affibody AB, Stockholm, Sweden

  ⨯
• Zohreh Varasteh,

  Affiliation Department of Medical Chemistry, Preclinical PET Platform, Uppsala University, Uppsala, Sweden

  ⨯
• Anna Orlova,

  Affiliation Department of Medical Chemistry, Preclinical PET Platform, Uppsala University, Uppsala, Sweden

  ⨯
• Vladimir Tolmachev,

  Affiliation Unit of Biomedical Radiations Sciences, Uppsala University, Uppsala, Sweden

  ⨯
• Stefan Ståhl ,

  * E-mail: stefans@biotech.kth.se

  Affiliation Division of Protein Technology, School of Biotechnology, KTH Royal Institute of Technology, Stockholm, Sweden

  ⨯
• John Löfblom

  Affiliation Division of Protein Technology, School of Biotechnology, KTH Royal Institute of Technology, Stockholm, Sweden

  ⨯